Finnish clinical phase biopharma company with over 20 years of history in biological drug development. The Company is focused on development and commercialization of its proprietary technology platform: Gene Transport Unit (GTU®). Currently, the Company employs 12 persons (+CEO) and has an experienced management as well as an internationally recognized scientific advisory board.
FIT Biotech was at first focused on development project of a HIV vaccine. GTU® technology platform was discovered during the project. As the commercial potential of GTU® emerged, the company shifted its strategy.
FIT Biotech is a technology company actively seeking application opportunities for GTU® and targeting licensing agreements with big pharma.